Innovation, intellectual property and access to medicines and vaccines: the international debate in the Covid-19 pandemic
DOI:
https://doi.org/10.18617/liinc.v16i2.5338Keywords:
Intellectual Property, Patent, Health, COVID-19, CoronavirusAbstract
This study analyses the international debate on various aspects access to health products, particularly medicines and vaccines, for Covid-19: innovation strategies such as drug repurposing, high-level public debate about vaccines as global public goods, intellectual property rights and TRIPS flexibilities, technology transfer agreements, and trade issues. The pandemic has concentrated intense technological efforts, which, in the future, may stimulate renewed public policies on science, innovation and production, state capabilities, public-private partnerships, and the strategic allocation of investments contributing to technological catching-up processes
References
ABBOTT, Frederick M. Compulsory licensing for public health needs: The TRIPS Agenda at the WTO after the Doha Declaration on Public Health”. 2008. Disponível em: https://quno.org/resource/2002/2/compulsory-licensing-public-health-needs. Acesso em: 03 ago. 2020.
BARBOSA, Pedro M. N. Licenças compulsórias e a covid-19. Disponível em: https://www.migalhas.com.br/depeso/324597/licencas-compulsorias-e-a-covid-19. Acesso em: 03 ago. 2020.
BEIGEL, John H.; TOMASHEK, Kay M.; DODD, Lori E.; MEHTA, Aneesh K; ZINGMAN, Barry S.; KALIL, Andre C. Remdesivir for the treatment of Covid-19 - preliminary report. 2020. Disponível em: doi: 10.1056/NEJMoa2007764. Acesso em: 03 ago. 2020. DOI: https://doi.org/10.1056/NEJMoa2007764
BERMUDEZ, Jorge; OLIVEIRA, Maria; CHAVES, Gabriela. Novos medicamentos: quem poderá pagar?. Cadernos de Saúde Pública, v. 32, supl. 2:e00025215, 2016. Disponível em: https://www.scielosp.org/article/csp/2016.v32suppl2/e00025215/pt/. Acesso em: 03 ago. 2020.
BOTTAZZII, Giulio et al. Innovation and corporate growth in the evolution of the drug industry. International Journal of Industrial Organization, v. 19 , n. 7, p. 1161-1187, 2001. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0167718701000686. Acesso em: 21 jul. 2020.
BUTANTAN. Butantan e Governo de SP vão testar e produzir vacina inédita contra coronavírus, 2020. Disponível em: http://www.butantan.gov.br/noticias/butantan-e-governo-de-sp-vao-testar-e-produzir-vacina-inedita-contra-coronavirus. Acesso em: 21 jul. 2020.
CASSIER, Maurice; CORREA, Marilena. Patents, innovation and public health: brazilian public-sector laboratories’ experience in copying AIDS drugs. Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. 2020. Disponível em: https://halshs.archives-ouvertes.fr/halshs-02162784. Acesso em: 21 jul. 2020.
CHAMAS, Claudia; REIS, Roberto. Saúde pública, patentes e exclusividade de dados de testes clínicos. In: BAIOCCHI, Enzo; SICHEL, Ricardo Luiz (org.). 20 anos da lei nº 9.279/1996: lei da propriedade industrial. Rio de Janeiro: Lumen Juris, 2018.
DOSI, Giovanni. The nature of the innovative process. In: DOSI, Giovanni et al. (Ed.). Technical change and economic theory. London: Pinter, 1988.
FIGUEIREDO, Paulo. Aprendizagem tecnológica e inovação industrial em economias emergentes: uma breve contribuição para o desenho e implementação de estudos empíricos e estratégias no Brasil. Revista Brasileira de Inovação, v. 3, n. 2, 323-361, 2004. Disponível em: https://periodicos.sbu.unicamp.br/ojs/index.php/rbi/article/view/8648901. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.20396/rbi.v3i2.8648901
FIOCRUZ. Fiocruz e AstraZeneca alinham detalhes para produção de vacina para Covid-19. 2020a. Disponível em: https://portal.fiocruz.br/noticia/fiocruz-e-astrazeneca-alinham-detalhes-para-producao-de-vacina-para-covid-19. Acesso em: 21 jul. 2020.
FIOCRUZ. Covid-19: medida provisória garante produção de vacina. 2020b. Disponível em: https://agencia.fiocruz.br/covid-19-medida-provisoria-garante-producao-de-vacina Acesso em: 21 jul. 2020.
FOLEGATTI, Pedro M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020. Disponível em: doi:10.1016/S0140-6736(20)31604-4. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
GADELHA, Carlos; QUENTAL, Cristiane; FIALHO, Beatriz. Saúde e inovação: uma abordagem sistêmica das indústrias da saúde. Cadernos de Saúde Pública, v. 19, n. 1, p. 47-59, 2003. Disponível em: https://www.scielo.br/scielo.php?pid=S0102-311X2003000100006&script=sci_abstract&tlng=pt DOI: https://doi.org/10.1590/S0102-311X2003000100006
GILEAD. Voluntary licensing agreements for remdesivir. 2020. Disponível em: https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir. Acesso em: 21 jul. 2020.
GORDON, Douglas; SAMANT, Vijay B. “The vaccine industry.” Plotkin's Vaccines, n. 48, 2020. Disponível em: https://www.sciencedirect.com/book/9780323357616/plotkins-vaccines. Acesso em: 21 jul. 2020.
G20. G20 trade and investment ministerial statement. Disponível em: http://www.g20.utoronto.ca/2020/2020-g20-trade-0330.html. Acesso em: 21 jul. 2020.
GUARASCIO, Francesco; POLLINA, Elvira. EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags – sources.Reuters. 2020. Disponível em: https://www.reuters.com/article/us-health-coronavirus-eu-vaccines-exclus/exclusive-eu-talks-with-pfizer-sanofi-jj-on-covid-vaccines-hit-snags-sources-idUSKCN24S1YQ. Acesso em: 21 jul. 2020.
HASENCLEVER, Lia; PARANHOS, Julia; PAIVA, Vitor. A extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricos. Reciis, n. 2, p. 50-57, 2008. Disponível em: https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.3395/reciis.v2i2.193pt
MAHASE, Elisabeth. Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy. 2020. Disponível em: https://www.bmj.com/content/369/bmj.m2612. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.1136/bmj.m2612
NEBEHAY, Stephanie. WHO decries 'vast global gap' in funds needed to fight coronavirus. 2020. Disponível em: https://www.reuters.com/article/us-health-coronavirus-who/who-decries-vast-global-gap-in-funds-needed-to-fight-coronavirus-idUSKCN25614V. Acesso em: 21 jul. 2020.
ORSENIGO, Luigi; DOSI, Giovanni; MAZZUCATO, Mariana. The dynamics of knowledge accumulation, regulation and appropriability in the pharma-biotech sector: policy issues. In: DOSI, Giovanni; MAZZUCATO, Mariana. Knowledge Accumulation and Industry Evolution. Cambridge, UK: Cambridge University Press, 2006.
PARANHOS, Julia; MERCADANTE, Eduardo; HASENCLEVER, Lia. Os esforços inovativos das grandes empresas farmacêuticas no Brasil: o que mudou nas duas últimas décadas?. Revista Brasileira de Inovação, v. 19, p. e0200015, 2020. Disponível em: https://periodicos.sbu.unicamp.br/ojs/index.php/rbi/article/view/8655780. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.20396/rbi.v19i0.8655780
RAY, Amit. The changing structure of R&D incentives in India: the pharmaceutical sector. Science Technology and Society, v. 9, n. 2, p. 297-317, 2004. Disponível em: https://journals.sagepub.com/doi/abs/10.1177/097172180400900205. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.1177/097172180400900205
SACRAMENTO Carolina Q. et al. The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. 2020. Disponível em: https://doi.org/10.1101/2020.06.15.153411. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.1101/2020.06.15.153411
SENANAYAKE, Suranga L. Drug repurposing strategies for COVID-19. Future Drug Discov, v. 0, n. 0, 2020. Disponível em: doi:10.4155/fdd-2020-0010. Acesso em: 21 jul. 2020. DOI: https://doi.org/10.4155/fdd-2020-0010
SILVERMAN, Ed. AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license. Stat, 2020. Disponível em: https://www.statnews.com/pharmalot/2020/03/20/abbvie-israel-hiv-kaletra-coronavirus-covid19/. Acesso em: 21 jul. 2020.
SYAM, Nirmalya. WTO TRIPS Council discusses national IP measures and TRIPS flexibilities in the context of COVID-19. 2020. Disponível em: https://us5.campaign-archive.com/?u=fa9cf38799136b5660f367ba6&id=184960e08b. Acesso em: 05 jun. 2020.
THE RECOVERY COLLABORATIVE GROUP. Dexamethasone in hospitalized patients with Covid-19: preliminary report. 2020. Disponível em: DOI: 10.1056/NEJMoa2021436. Acesso em: 05 jun. 2020. DOI: https://doi.org/10.1056/NEJMoa2021436
UNITAID. Medicines patent pool and unitaid respond to access efforts for COVID-19 treatments and technologies. Geneva: UNITAID, 2020. Disponível em: https://unitaid.org/news-blog/medicines-patent-pool-and-unitaid-respond-to-access-efforts-for-covid-19-treatments-and-technologies/#en. Acesso em: 21 jul. 2020.
UNITED NATIONS. Shared responsibility, global solidarity: responding to the socio-economic impacts of COVID-19. NY, 2020. Disponível em: https://data2.unhcr.org/en/documents/details/75741. Acesso em: 21 jul. 2020.
WANG, Chen et al. A novel coronavirus outbreak of global health concern. The Lancet, v. 395, n. 10223, 2020.
WHO. Global preparedness monitoring board: a world at risk: annual report on global preparedness for health emergencies. Geneva: WHO, 2019. Disponível em: https://apps.who.int/gpmb/annual_report.html. Acesso em: 05 jun. 2020.
WHO. Pneumonia of unknown cause – China. Geneva, WHO, 2020a. Disponível em: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Acesso em: jun. 2020.
WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Geneva, WHO, 2020b. Disponível em: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Acesso em: 05 jun. 2020.
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19. Geneva: WHO, 2020c. Disponível em: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Acesso em: 20 jul. 2020.
WHO. COVAX: working for global equitable access to COVID-19 vaccines. Geneva: WHO, 2020d. Disponível em: https://www.who.int/initiatives/act-accelerator/covax. Acesso em: 12 ago. 2020.
WHO. WHO Director-General's opening remarks at the media briefing on COVID-19. Geneva: WHO, 2020e. Disponível em: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---10-august-2020. Acesso em: 21 jul. 2020.
WHO. International community rallies to support open research and science to fight COVID-19. Geneva: WHO, 2020f. Disponível em: https://www.who.int/news-room/detail/29-05-2020-international-community-rallies-to-support-open-research-and-science-to-fight-covid-19. Acesso em: 21 jul. 2020.
WHO; WIPO; WTO. Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade. Geneva: WHO, 2020. Disponível em: https://www.wipo.int/publications/en/details.jsp?id=4511. Acesso em: 21 jul. 2020.
WTO. Joint statement by WTO Director-General Roberto Azevêdo and WHO Director-General Tedros Adhanom Ghebreyesus. Geneva: WHO, 2020a. Disponível em: https://www.wto.org/english/news_e/news20_e/igo_14apr20_e.htm. Acesso em: 21 jul. 2020.
WTO. WTO members stress role of IP system in fighting COVID-19. Geneva: WHO 2020b. Disponível em: https://www.wto.org/english/news_e/news20_e/trip_30jul20_e.htm. Acesso em: 21 jul. 2020.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant Liinc em Revista the right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License.
The authors have permission and are encouraged to deposit their manuscripts and versios of record (VoR) in their personal web pages or institutional repositories, generic repositories etc., before (pre-print) or after (post-print) the publication in Liinc em Revista, according to its open access depositing policy registered in the Directory of Editorial Policies of Brazilian Journals (DIADORIM), kindly providing a link to the article published on Liinc's website.
Liinc em Revista, published by Instituto Brasileiro de Informação em Ciência e Tecnologia, is licensed under a Creative Commons Attribution 4.0 International License – CC BY 4.0 
How to Cite
